Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671
Recruiting
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Gender:
FEMALE
Ages:
15 years and above
Trial Updated:
05/19/2025
Locations: Research Site, Birmingham, Alabama +190 locations
Conditions: Locally Advanced Cervical Cancer
Register for Updates
An Acupuncture Study for People At High Risk for Sepsis
NCT06344819
Recruiting
Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham acupuncture is performed the same way as real acupuncture but will use different needles and target different sites or places on the body than real acupuncture.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Sepsis
Register for Updates
Investigation to Understand and Optimize Psilocybin
NCT06512194
Recruiting
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be assoc... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/19/2025
Locations: Vail Health Behavioral Health, Edwards, Colorado
Conditions: Depression
Register for Updates
ShotBlocker During Intramuscular Injection Randomized Control Trial
NCT06624176
Recruiting
The objective of this trial is to evaluate the effect of Bionix ShotBlocker on pain of injection of the first Hepatitis B vaccine in healthy newborns. ShotBlocker is a pain reducing tool used in babies, children, and adults for injections. Swaddling during the injection and administration of oral sucrose prior to the injection are established standards of care for painful procedures in neonates. The investigators hypothesize that the use of ShotBlocker in addition to swaddling and oral sucrose a... Read More
Gender:
ALL
Ages:
Between 37 weeks and 42 weeks
Trial Updated:
05/19/2025
Locations: UMass Memorial Medical Center- Memorial Campus, Worcester, Massachusetts
Conditions: Neonatal Pain
Register for Updates
ARIADNE Clinical Trial
NCT06747091
Recruiting
A prospective multi-arm parallel group randomized clinical trial to compare the efficacy of three ablation strategies in patients with persistent atrial fibrillation using using a lattice-tip catheter that can switch between RFA and PFA energy. The incremental benefit of posterior wall isolation (PWI) and mitral isthmus ablation may contribute to greater freedom from atrial fibrillation at twelve months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/19/2025
Locations: North Shore University Hospital, Manhasset, New York +2 locations
Conditions: Persistent Atrial Fibrillation
Register for Updates
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06961370
Recruiting
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/19/2025
Locations: Global Research Management, Glendale, California +4 locations
Conditions: Geographic Atrophy, Age-related Macular Degeneration
Register for Updates
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
NCT02842424
Recruiting
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities. The most common clinical manifestation of PAD is claudication, i.e., a severe functional limitation identified as gait dysfunction and walking-induced leg muscle pain relieved by rest. The standard therapies for claudication include the medications cilostazol and pentoxifylline, supervised exercise therapy and operative revascula... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/19/2025
Locations: VA Medical Center, Omaha, Nebraska
Conditions: Peripheral Arterial Disease
Register for Updates
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
NCT04421560
Recruiting
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
Register for Updates
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama (UAB), Birmingham, Alabama +21 locations
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Register for Updates
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
NCT05474846
Recruiting
To learn if Cognitive Behavior Therapy (called CBT), combined with either Bright Light Therapy (called BLT), methylphenidate, and/or melatonin, can help improve sleep and other related symptoms such as fatigue, anxiety, and depression in cancer patients. This is an investigational study. In this study, BLT, Methylphenidate and Melatonin will be compared to their placebos.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Sleep, Fatigue, Anxiety, Cancer, Depression
Register for Updates
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259
Recruiting
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California +9 locations
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
iTBS to Enhance Social Cognition in People With Psychosis
NCT06118268
Recruiting
The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychotic disorder not otherwise specified. The main objectives of this trial are: * Compare changes in social cognitive performance between the active vs. sham treatment groups * Compare changes in social cognitive network functional connectivity between the a... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
05/19/2025
Locations: Zucker Hillside Hospital, Glen Oaks, New York
Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
Register for Updates